HESTERBIO Hester Bios Q4 FY26 results (Jan–Mar 2026) and concall
Hester Biosciences reported a strong Q4 and FY26, driven by robust performance in its Poultry Healthcare division, which saw significant revenue and PAT growth. The company also achieved key milestones with the H9N2 vaccine and facility capitalization. However, the Animal Healthcare division faced headwinds due to tender delays, and concerns were raised regarding high receivables and bad debt write-offs, which management is actively addressing. The company remains focused on operational efficiency and strategic market penetration.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 22.1%, net profit up 160.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 74 | 63 | 77 | 63 | 65 −12% | 70 +11% | 94 +22% |
| EBITDA | 15 | 9 | 14 | 12 | 12 −20% | 17 +89% | 31 +121% |
| Net profit | 9 | 4 | 10 | 8 | 7 −22% | 11 +175% | 26 +160% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
